Issue link: https://www.e-digitaleditions.com/i/1218534
Tablets & Capsules March 2020 9 The agency also approved Dificid (fidaxomicin) tablets and oral sus- pension for use in pediatric patients 6 months of age and older for the treatment of Clostridioides difficile associated diarrhea (CDAD), provid- ing a new formulation for pediatric patients. Dificid tablets were previ- ously approved for the treatment of CDAD in adults 18 years and older. The treatment is manufactured by Merck, Kenilworth, NJ. Strides Pharma Science, Banga- lore, India, received FDA approval for its loratadine softgel capsule product, a generic version of Claratin Liqui-Gels, manufactured by Bayer HealthCare. The antihistamine prod- uct treats the symptoms of hay fever and other allergies. The FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride) to lower blood sugar in adults with type-2 diabetes. The treatment, marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly, provides three type-2 diabetes medicines in one tablet product. $26-million expansion included a renovation of 12,000 square feet of existing rooms to provide modern research labs and associated support space, a 20,000-square-foot, two- story addition, and an expansion of the college's History of Phar- macy museum. The new chemistry laboratories will be used for drug discovery and development and research in pharmaceutics, pharma- cogenomics, and pharmacology and will provide greater research oppor- tunities for students enrolled in the college's undergraduate, graduate, and postdoctoral programs. Briefly noted… The FDA granted accelerated approval to Tazverik (tazemetostat), a treatment for adults and pediatric patients ages 16 and older with met- astatic or locally advanced epitheli- oid sarcoma that are not eligible for complete resection. It is manufac- tured by Epizyme, Cambridge, MA. FDA approves first peanut allergy treatment for children SILVER SPRING, MD—The FDA approved Palforzia, a peanut (Ara- chis hypogaea) allergen powder that mitigates allergic reactions, includ- ing anaphylaxis, that may occur with accidental exposure to peanuts. The treatment can be administered to patients ages 4 to 17 with a diag- nosed peanut allergy. The powder is manufactured from peanuts and is packaged in color-coded, pull-apart capsules and sachets. It is manufac- tured by Aimmune Therapeutics, a biopharmaceutical developer of food allergy treatments headquartered in Brisbane, CA. University of Arizona renovates pharmaceutical center TUCSON, AZ— The University Of Arizona's College Of Pharmacy opened its newly expanded Skaggs Pharmaceutical Sciences Center, which will house the Arizona State Center for Drug Discovery. The